Global expansion Cube Biotech is actively pursuing long-term collaborations with industrial and academic partners and has announced leadership changes and expansion plans in 2025, signaling growing demand and opportunities for contract research services, especially in membrane protein research and GPCR-targeted therapeutics.

Strategic partnerships Recent collaborations and acquisitions, including with Isogenica for GPCR technology integration and the acquisition of IBA Lifesciences, indicate a strategy of expanding capabilities and offering integrated solutions, presenting cross-sell and co-development sales opportunities.

AI and automation Engagement with AI-enabled drug discovery (Iktos collaboration) and a scalable protein technology platform suggest potential for joint ventures or service expansions in computational design, protein stabilization, and accelerated hit-to-lead workflows.

Membrane protein focus Cube Biotech differentiates with a proprietary synthetic copolymer portfolio enabling native-like membrane protein research, which can be pitched to drug discovery teams needing robust GPCR, transporter, and complex membrane protein targets.

Flexible commercial models You offer FTE-based, fee-for-service-based, and milestone-based engagement models, allowing tailored partnerships with pharma, biotech, and academia, and enabling rapid quote-to-pilot opportunities to accelerate decision making.